



Viridis Mining and Minerals Ltd (VMM.ASX)

Attractive PFS and strategic funding pave way to production

Event:

- PFS review; Equity placement; PT change.

Investment Highlights:

- **Stronger PFS metrics.** VMM's Colossus PFS upgrades key metrics vs the February 2025 scoping study (SS), maintaining a 5Mtpa plant targeting 9.4ktpa REO (3.5ktpa MREO) over 20 years from 2028. At US\$90/kg NdPr, post-tax NPV₈ rises 5% to US\$899M and IRR lifts to 34% (from 31%) with a fast 2-year payback.
- **NPV/capex improves to 2.5x.** Capex drops 4% to US\$358M, lowering capex intensity to US\$72/t (from US\$75/t) and boosting NPV/capex to an attractive 2.5x (from 2.3x). The improvement stems mainly from reduced import taxes (US\$40M vs US\$56M) via partial state-level tax relief, and a lower contingency (25% vs 30%) reflecting greater confidence in cost estimates. This offsets higher direct costs (US\$185M vs US\$167M), driven by detailed engineering and design adjustments to enhance operations and meet environmental standards.
- **Low cost for long-life operation.** Unit cost was slightly up by 3%, with C1 cost lifted to US\$6.20/kg TREO (from US\$6.00/kg) and US\$16.60/kg MREO (from US\$16.20/kg), largely due to more detailed vendor quotes. The PFS replaces the SS's conservative opex risk margin with real June 2025 quotes, enabling a more accurate view of operating cashflows. Colossus remains firmly in the lowest cost quartile globally. More upside from pending federal incentives.
- **Robust economics even at spot.** Colossus remains cash-generative even at weak spot prices, delivering US\$128M in annual operating cash flow and a 3-year payback at US\$63/kg NdPr. It stays cash-positive down to US\$50/kg, highlighting strong price resilience. Further upside remains with the PFS only reflecting 13% of the land and 20% of the Resource.
- **Commissioning targeted for 2028.** Preliminary Licence is expected this quarter, with Construction Licence by May 2026 and Operating Licence in late 2H 2027. We assume FID by 2H 2026 and first production by 2H 2028.
- **Key strategies to provide funding.** VMM's \$11.5M equity raise lifts pro-forma cash to ~\$13M, funding FID workstreams: demo plant, drilling, permitting, and DFS. Cornerstoned by JGP Asset Management (\$5M), the raise follows a binding MOU on staged placement pathway (US\$30M) with ORE Investments and Regia Capital. VMM is also shortlisted for BNDES/FINEP's R\$5b (US\$903M) program.

Earnings and Valuation:

- **Share valuation rises to \$2.64 (0.5x NPV₁₀ nominal)** from \$1.77 mainly on lower capex, increase in our long-term NdPr price to US\$104/kg from US\$97/kg and lower risk factor of Colossus as a result of the PFS, offset partially by equity dilution post-placement and higher operating costs.

Recommendation:


- **We maintain our Buy, increasing our 12-month price target to \$2.64** from \$1.77 based on valuation. Catalysts: 1) Resource upgrade; 2) DFS; 3) Preliminary licence; 4) demo plant; and 5) Offtakes/financing.

Disclosures

Foster Stockbroking, staff, and Cranport own 1.4% of VMM's shares on issue.

Foster Stockbroking earned fees from its role as Joint Lead Manager to the \$11.5M placement at \$0.91 in July 2025; \$3.5M placement at \$0.33 in February 2025, and \$4M placement at \$0.52 in October 2024.

Recommendation	Buy
Previous	Buy
Risk	High
Price Target	\$2.64
Previous	\$1.77
Share price (A\$)	\$1.06
ASX code	VMM
52 week low-high	\$0.18-1.19
Valuation - risked (A\$/share)	\$2.64
Methodology	NPV10
Capital structure	
Shares on Issue (M)	99
Market cap (A\$M)	105
Estimated current net cash (debt) (A\$M)	13
Diluted EV (A\$M)	92
Ave daily volume ('000)	323
Substantial shareholders	%
Sufian Ahmad	7.8%
Bilal Ahmad	6.1%
Agha Pervez	5.8%
Ionic Rare Earths Ltd	3.2%
Board	
Agha Pervez	Executive Chairman
Rafael Moreno	MD/CEO
Jose Guedes	Non-Executive Director
Christopher Gerteisen	Non-Executive Director
Timothy Harrison	Non-Executive Director
Faheem Ahmed	Non-Executive Director
Share price graph	



Analyst: Hazmy Hazin
hazmy.hazin@fostock.com.au

+612 9993 8130



Viridis Mining and Minerals (VMM)

Full Year Ended 30 June

Profit and Loss A\$M	2024a	2025e	2026e	2027e
Revenue	0	0	0	0
Operating costs adj.	7	7	3	3
EBITDA adj.	-7	-8	-4	-4
D&A	0	0	0	0
EBIT adj.	-7	-8	-4	-4
Net Interest exp / (income)	0	0	0	0
PBT adj.	-7	-8	-4	-4
Tax exp / (benefit) adj.	0	0	0	0
NPAT adj.	-7	-8	-4	-4
Non-recurring items	-1	0	0	0
NPAT reported	-8	-8	-4	-4
EPS diluted adj. (c)	-14.03	-12.44	-5.43	-4.74

Cashflow A\$M	2024a	2025e	2026e	2027e
EBITDA adj.	-7	-8	-4	-4
Change in WC	-2	-1	-1	-1
Tax	0	0	0	0
Net interest	0	0	0	0
Share based expense	0	0	0	0
Other	7	7	10	30
Operating Cashflow	-2	-2	5	25

Capex	0	0	0	0
Exploration	-11	-5	-4	-5
Investments	0	0	0	0
Acquisition	0	-3	0	0
Other	0	0	0	0
Investing Cashflow	-11	-8	-4	-5

Equity issue	17	13	19	20
Debt repayments	0	0	0	0
Debt borrowed	0	0	0	0
Other	0	-1	-1	-11
Financing Cashflow	17	13	18	9

Net Cashflow	4	3	17	29
---------------------	----------	----------	-----------	-----------

Balance Sheet A\$M	2024a	2025e	2026e	2027e
Cash	5	4	21	50
Receivables	0	0	0	0
Inventories	0	0	0	0
PPE	0	0	0	0
Other	16	19	14	0
Total Assets	22	23	36	51
Accounts payable	1	2	2	1
Provisions	0	0	0	0
Debt	0	0	0	0
Other	0	12	1	5
Total Liabilities	1	14	4	7
Capital & reserves	53	41	60	80
Retained earnings	-32	-32	-28	-36
Total Equity	21	9	32	44

Company Valuation				
DCF, WACC 10% nominal				
Segment	Unrisked A\$M	Unrisked A\$/sh	Risked A\$M	Risked A\$/sh
Colossus 5Mtpa Scoping Study	1,942	\$3.64	1,000	\$1.87
Colossus - remaining resources - delta	402	\$0.75	80	\$0.15
Other exploration projects	9	\$0.02	2	\$0.00
Expansion to 10Mtpa - delta	397	\$0.74	79	\$0.15
Corporate	-67	-\$0.12	-67	-\$0.12
Net Cash	13	\$0.02	13	\$0.02
Future equity	302	\$0.57	302	\$0.57
Cash from options	1	\$0.00	1	\$0.00
Total	3,000	\$5.62	1,411	\$2.64

Shares on issue	99	99
Future shares	228	426
Performance rights	7	7
Options	2	2
Diluted shares	336	534

Commodity Assumptions		2024a	2025e	2026e	2027e
Prices:					
NdPr	US\$/kg	64	79	94	101
Dy ₂ O ₃	US\$/kg	274	288	325	391
Tb ₄ O ₇	US\$/kg	944	1,054	1,179	1,262
TREO Basket	US\$/kg	23	27	32	34
MREO Basket	US\$/kg	20	24	29	31
NdPr Basket	US\$/kg	16	19	23	25
A\$	US\$	0.65	0.64	0.66	0.67

JORC Resources	Ore Mt	TREO ppm	NdPr ppm	Dy ₂ O ₃ ppm	Tb ₄ O ₇ ppm
Colossus - REE	493	2,508	571	26	5

Capital structure	M
Shares on issue	99
Performance rights	7
Options	2
Diluted shares	108

Source: Company; Foster Stockbroking estimates

COLOSSUS PFS

Net positive vs scoping: higher NPV, low opex, attractive capex

- PFS for Colossus marks an upgrade over the February 2025 Scoping Study, with stronger bottom-line economics. As shown in Figure 1, the PFS delivers higher value while retaining the 5Mtpa plant design, targeting 9.4ktpa REO (3.5ktpa MREO) over a 20-year life starting 2028.
- Key positive changes from the PFS include a 5% lift in post-tax NPV₈ to US\$899M from US\$859M, IRR rising to 34% from 31% and generating annual operating cashflow (ex-capex) of US\$197M (+53%) — all while reducing capex by 4% to US\$358M from US\$373M.
- Similar to SS, the PFS examined Colossus economics across three price scenarios:
 - Spot Case at US\$63/kg NdPr, showing robust free cash flow even at cyclical lows;
 - conservative Base Case at US\$90/kg NdPr, aligned with Project Blue's 2028 forecast and below typical peer assumptions; and
 - Upside Case at US\$111/kg NdPr, based on the average REE price from Project Blue's 2028–2034 forecast, highlighting significant upside if the market tightens further.
- Consistent with the SS, the PFS mine plan is based on 98.5Mt of Resources (0.7% Measured, 99.3% Indicated) sourced solely from the Northern concessions and Cupim South — just 20% of Colossus's total 493Mt Resource @ 2,508ppm TREO (24% MREO). The upgraded January Resource includes an Inferred component, which was excluded from the study. The PFS also does not cover other key areas such as Tamoyos, Ribeirão, and Capão da Onça.

Figure 1: Colossus PFS at US\$90/kg


Parameter	Unit	Scoping Feb 2025	PFS Jul 2025	PFS vs Scoping
Life of mine	Years	20	20	0%
Commodities:				
NdPr ave. LOM	US\$/kg	90	90	0%
MREC Basket price	US\$/kg	43	43	0%
MREC Payability	%	70%	70%	0%
Mining and production:				
Strip ratio	x	0.4	0.4	0%
Mine inventory	Mt	99	99	0%
Ore processed:	Mtpa	5	5	0%
TREO head grade	ppm	3,383	3,380	0%
MREO recovery	%	76%	76%	0%
TREO contained ave.	ktpa	9.4	9.4	0%
NdPr contained ave.	ktpa	3.4	3.4	0%
DyTb contained ave.	tpa	141	145	3%
Financials:				
Sales average	US\$M pa	282	282	0%
C1 operating cost	US\$/kg TREO	6.0	6.2	3%
C1 operating cost	US\$/kg MREO	16.2	16.6	2%
AISC	US\$/kg TREO	8.8	9.3	6%
Pre-production capex (5Mtpa)	US\$M	373	358	-4%
NPV post-tax*	US\$M	859	899	5%
*Discount rate		8%	8%	n/a
NPV/capex	x	2.3	2.5	9%

Source: Company; Foster Stockbroking estimates.

Capex and opex remains attractive

- Capex overall lower at US\$358M (-4%), implying lower capex intensity of US\$72/t (from US\$75/t) and boosting NPV/capex to an attractive 2.5x (from 2.3x). The improvement stems mainly from reduced import taxes (US\$40M vs US\$56M) via partial state-level tax relief, and a lower contingency (25% vs 30%) reflecting greater confidence in cost estimates. This offsets higher direct costs (US\$185M vs US\$167M), driven by detailed engineering and design adjustments to enhance operations and meet environmental standards.
- Unit cost was up but only around 3%, with C1 cost lifted to US\$6.20/kg TREO (from US\$6.00/kg) and US\$16.60/kg MREO (from US\$16.20/kg), largely due to more detailed vendor quotes. The PFS replaces the SS's conservative opex risk margin with real June 2025 quotes, enabling a more accurate view of operating cashflows and contributing to a 53% jump in annual operating cashflow (ex-capex) to US\$197M. Colossus remains firmly in the lowest cost quartile globally and among the leading REE projects ex-China.
- AISC is estimated at just US\$9.30/kg TREO (from US\$8.80/kg), underpinning long-term margin resilience. Fiscal optimisation adds further value, with VMM securing state-level tax exemptions and deferrals, while additional federal incentives are under negotiation — further enhancing project returns.
- Colossus remains cash-generative even at weak spot prices, delivering US\$128M in annual operating cash flow and a 3-year payback at US\$63/kg NdPr. It stays cash-positive down to US\$50/kg, highlighting strong price resilience.
- Mining will start in the Northern Concessions, close to the central plant, avoiding early investment in long-haul roads and enabling early cost optimisation. The first five years will target high-grade MREO pits near the plant, maximising cash flow and accelerating payback. Later, operations will expand into the Southern Complex (Cupim South) to optimise resource use and enhance flexibility. VMM has also adopted in-pit backfilling from the outset, eliminating the need for tailings dams and large waste dumps — reducing the surface footprint and long-term environmental liabilities.

Figure 2: Rare earth industry cost curve for February 2025



Source: Project Blue Consulting.



Optimisation

- Further improvement opportunities ahead, including potential Resource growth, as the current Resource covers just 13% of its land and 20% of the Resource. The most advanced opportunity is the high-grade Centro Sul and Tamoyo deposit – which may extend mine life >20 years and/or expanding mining rate (e.g. 10Mtpa). VMM is also optimising the flowsheet to enhance efficiency and further reduce the capex and opex.

KEY STRATEGICS TO PROVIDE FUNDING

Binding MoU for funding from ORE and Regia Capital


- VMM secured a landmark strategic partnership with Brazil's leading financial institutions, ORE Investments and Régia Capital, via a binding MoU for up to US\$30M (A\$46M) in staged, non-brokered equity funding to support Colossus through FID and into early execution. The structure provides capital flexibility across four tranches over 36 months, beginning with an initial US\$5M injection at A\$0.91/share later this year.
- With Colossus' strong PFS now released, the company is well-positioned to attract further strategic funding from other sources as well amid rising geopolitical urgency around critical minerals, recently reinforced by Trump's tariffs. The PFS boosts its appeal to corporates and governments seeking secure, low-cost REE supply outside China.
- VMM also recently raised A\$11.5M at A\$0.91/share, boosting its pro forma cash to ~A\$12.7M and fully funding it through to FID. The raise attracted strong institutional support, including a A\$5M cornerstone investment from Brazil's JGP Asset Management, reinforcing confidence in Colossus.
- The ORE Investment/Regia Capital partnership brings not only capital depth but also in-country expertise, ESG alignment, and strong regulatory networks, significantly de-risking the development pathway. VMM retains full financing optionality while gaining access to Brazil's top-tier mining and investment circles, positioning the company to accelerate permitting, the MREC demonstration plant, DFS, and early-stage execution with minimal dilution and strong strategic backing.
- VMM and its JV entity Viridion have also been selected by Brazil's top development agencies, BNDES and FINEP, to progress under a Joint Support Plan (PSC) — a major endorsement unlocking potential access to Brazil's US\$903M strategic minerals fund. This selection, based on Colossus's strong PFS economics, and downstream integration via patented IXR technology, positions VMM to negotiate a tailored funding package that may include grants, debt, and equity. The funding will accelerate Colossus' development and downstream refining, with VMM also eligible for Brazil's additional US\$542M innovation pool aimed at value-added critical minerals, unlocking further non-dilutive capital pathways.
- Meanwhile, VMM continues to actively engaging strategic offtakers and financiers, including export credit agencies, targeting a funding mix of strategic equity and debt from mining corporates and government-linked entities like the US DoE and DoD, with the PFS expected to accelerate these discussions. US rare earths interest remains strong, highlighted by MP Materials' recent DoD partnership.

TIMELINE

Commissioning targeted 2H 2028

- VMM is expecting to receive Preliminary Licence this quarter, with Construction Licence by May 2026 and Operating Licence in late 2H 2027. We assume FID by 2H 2026 and first production by 2H 2028. Other key milestone for VMM is a Resource upgrade with maiden Reserve and completion of the DFS by 2H 2026.

Figure 3: Colossus Timeline



Source: Company.

VALUATION

Increased to \$2.64 from \$1.77

- Our risked VMM share valuation (0.5x NPV₁₀ nominal) is increased to \$2.64 from \$1.77, mainly due to lower capex and increase in our long-term NdPr price forecast to US\$104/kg from US\$97/kg, partially offset by higher equity dilution assumptions and higher unit operating costs and reducing our risk factor of Colossus as a result of the PFS.

Figure 4: VMM Valuation

Segment	Unrisked		Risked	
	A\$M	A\$/sh	A\$M	A\$/sh
Colossus – 5Mtpa, 20 Yr LOM	1,949	\$3.73	980	\$1.88
Mining other Resources – delta	402	\$0.77	80	\$0.15
10Mtpa expansion - delta	390	\$0.75	78	\$0.15
Corporate & working capital	-67	-\$0.13	-67	-\$0.13
Net cash	13	\$0.02	13	\$0.02
Future equity	294	\$0.56	294	\$0.56
Cash from options	1	\$0.00	1	\$0.00
Total	2,992	\$5.72	1,382	\$2.64
Shares on issue			99	
Future shares*			414	
Performance shares			3	
Performance rights			4	
Options			2	
Diluted shares			523	

*Risked assumes raised at near current share price.

Source: Foster Stockbroking estimates

RECOMMENDATION

Maintain Buy, 12-month price target increased to \$2.64 from \$1.77

- We maintain our Buy on VMM, increasing our 12-month price target to \$2.64 from \$1.77, based on our risked valuation of 0.5x NPV₁₀ nominal.
- We see key catalysts for the stock including: 1) Resource upgrade; 2) DFS; 3) Preliminary licence; 4) demo plant; and 5) Offtakes and financing.

FOSTER STOCKBROKING DISCLOSURES

Name	Department	Phone	Email
Stuart Foster	Chief Executive Officer	+61 2 9993 8131	stuart.foster@fostock.com.au
David Salmon	Institutional Sales	+61 2 9993 8168	david.salmon@fostock.com.au
Doc Cromme	Institutional Sales	+61 2 9993 8132	doc.cromme@fostock.com.au
Jason Lal	Institutional Sales	+61 2 9993 9814	jason.lal@fostock.com.au
Max Gould	Institutional Sales	+61 2 9993 8143	max.gould@fostock.com.au
Ellie Bedoyan	Corporate	+61 2 9993 8122	ellie.bedoyan@fostock.com.au
Mark Fichera	Head of Research	+61 2 9993 8162	mark.fichera@fostock.com.au
Hazmy Hazin	Research Analyst	+61 2 9993 8130	hazmy.hazin@fostock.com.au

Foster Stockbroking Pty Ltd
A.B.N. 15 088 747 148 AFSL No. 223687
Sydney: Level 9, 275 George Street, Sydney, NSW 2000 Australia
General: +612 9993 8111 Equities: +612 9993 8100 Fax: +612 9993 8181
<http://www.fostock.com.au>
Email: contact@fostock.com.au
PARTICIPANT OF ASX GROUP

Foster Stockbroking recommendation ratings: Buy = return >10%; Hold = return between -10% and 10%; Sell = return <-10%. Speculative Buy = return > 20% for stock with high risk. All other ratings are for stocks with low-to-high risk. Returns quoted are annual.

Disclaimer & Disclosure of Interests. Foster Stockbroking Pty Limited (**Foster Stockbroking**) has prepared this report by way of general information. This document contains only general securities information or general financial product advice. The information contained in this report has been obtained from sources that were accurate at the time of issue, including the company's ASX releases which have been relied upon for factual accuracy. The information has not been independently verified. Foster Stockbroking does not warrant the accuracy or reliability of the information in this report. The report is current as of the date it has been published.

In preparing the report, Foster Stockbroking did not take into account the specific investment objectives, financial situation or particular needs of any specific recipient. The report is published only for informational purposes and is not intended to be personal financial product advice. This report is not a solicitation or an offer to buy or sell any financial product. Foster Stockbroking is not aware whether a recipient intends to rely on this report and is not aware of how it will be used by the recipient. Before acting on this general financial product advice, you should consider the appropriateness of the advice having regard to your personal situation, investment objectives or needs. Recipients should not regard the report as a substitute for the exercise of their own judgment.

The views expressed in this report are those of the analyst/s named on the cover page. No part of the compensation of the analyst is directly related to inclusion of specific recommendations or views in this report. The analyst/s receives compensation partly based on Foster Stockbroking revenues, including any Corporate Services and proprietary trading revenues, as well as performance measures such as accuracy and efficacy of both recommendations and research reports.

Foster Stockbroking believes that the information contained in this document is correct and that any estimates, opinions, conclusions or recommendations are reasonably held or made at the time of its compilation in an honest and fair manner that is not compromised. However, no representation is made as to the accuracy, completeness or reliability of any estimates,



opinions, conclusions or recommendations (which may change without notice) or other information contained in this report. To the maximum extent permitted by law, Foster Stockbroking disclaims all liability and responsibility for any direct or indirect loss that may be suffered by any recipient through relying on anything contained in or omitted from this report. Foster Stockbroking is under no obligation to update or keep current the information contained in this report and has no obligation to tell you when opinions or information in this report change.

Foster Stockbroking does and seeks to do business with companies covered in research. As a result investors should be aware that the firm may have a conflict of interest which it seeks to manage and disclose.

Foster Stockbroking and its directors, officers and employees or clients may have or had interests in the financial products referred to in this report and may make purchases or sales in those financial products as principal or agent at any time and may affect transactions which may not be consistent with the opinions, conclusions or recommendations set out in this report. Foster Stockbroking and its Associates may earn brokerage, fees or other benefits from financial products referred to in this report. Furthermore, Foster Stockbroking may have or have had a relationship with or may provide or has provided capital markets and/or other financial services to the relevant issuer or holder of those financial products.

For an overview of the research criteria and methodology adopted by Foster Stockbroking; the spread of research ratings; and disclosure of the cessation of particular stock coverage, refer to our website <http://www.fostock.com.au>.

Specific disclosure: The analyst does not own VMM shares at the time of this report. Diligent care has been taken care by the analyst to maintain honesty and fairness in writing the report and making the recommendation.

Specific disclosure: The analyst has received assistance from the company in preparing the report, including reviewing it for factual accuracy.

Specific disclosure: Foster Stockbroking earned fees from its role as Joint Lead Manager to the \$11.5M placement of VMM shares at \$0.91 in July 2025; the \$3.5M placement at \$0.33 in February 2025; and the \$4M placement at \$0.52 in October 2024.

Specific disclosures: As of close of business 1 August 2025, Foster Stockbroking, staff, and Cranport owned 1.4% of VMM shares. The position may change at any time and without notice, including on the day that this report has been released. Foster Stockbroking and its employees may from time to time own shares in VMM, and trade them in ways different from those discussed in research. Foster Stockbroking may also make a market in securities of VMM, including buying and selling securities on behalf of clients.

Review disclosure: The report was authored by the analyst named on the front page of the report and was reviewed and checked by Mark Fichera, Head of Research.

Disclosure review. All the disclosures in the report have been reviewed and checked by Keith Quinn, Compliance.